Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Journey Medical CorporationNASDAQ: DERM

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $8.62M rose 18.3% year over year, ahead of the +7.6% change in trailing-twelve-month gross profit. Sequentially, it fell 10.0% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.

Context

  • Gross profit amounted to 59.3% of revenue in FY2025, down 3.5 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +18.3% holds above the trailing-twelve-month pace of +7.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.62M-10.0% QoQ
Last fiscal yearDec 2025
$36.68M+4.0% YoY
LTMMar 2026
$39.07M+7.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.3%——
1 year+4.0%——
3-year CAGR-5.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
36.68M USD
Year-over-year change
+4.0%
4-year CAGR
+4.3%

Gross Profit vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.6% is the 6th highest of 10, against a peer median of +54.0%.
  • Gross profit amounts to 60.4% of revenue for DERM, versus a peer median of 48.3%.
DERM Competitors
Gross Profit for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$97.71M CAD+54.0%—35.6%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$47.04M USD+68.6%+204.4%92.2%
OSUROraSure Technologies, Inc.LTM Mar 2026$46.35M USD-32.6%-31.3%41.0%
DERMJourney Medical CorporationLTM Mar 2026$39.07M USD+7.6%-5.1%60.4%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M USD+1115.8%+118.1%99.3%
HSDTSolana CompanyLTM Mar 2026$9.03M USD+6284.9%+157.3%94.2%
NYXHNyxoah S.A.LTM Mar 2026€7.89M EUR+175.8%+48.4%48.3%
MDWDMediWound Ltd.LTM Mar 2026$2.84M USD+2.7%-37.2%19.6%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$11.02M USD-132.3%-70.5%621.0%
Peer median (excluding DERM) —+54.0%+8.6%48.3%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.